Agios Pharmaceuticals Management

Management criteria checks 3/4

Agios Pharmaceuticals' CEO is Brian Goff, appointed in Aug 2022, has a tenure of 1.75 years. total yearly compensation is $3.42M, comprised of 23.4% salary and 76.6% bonuses, including company stock and options. directly owns 0.095% of the company’s shares, worth $1.86M. The average tenure of the management team and the board of directors is 2.3 years and 7.9 years respectively.

Key information

Brian Goff

Chief executive officer

US$3.4m

Total compensation

CEO salary percentage	23.4%
CEO tenure	1.8yrs
CEO ownership	0.09%
Management average tenure	2.3yrs
Board average tenure	7.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Brian Goff's remuneration changed compared to Agios Pharmaceuticals's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	-US$353m
Dec 31 2023	US$3m	US$798k	-US$352m
Sep 30 2023	n/a	n/a	-US$220m
Jun 30 2023	n/a	n/a	-US$210m
Mar 31 2023	n/a	n/a	-US$218m
Dec 31 2022	US$12m	US$308k	-US$232m

Compensation vs Market: Brian's total compensation ($USD3.42M) is above average for companies of similar size in the UK market ($USD2.16M).

Compensation vs Earnings: Brian's compensation has been consistent with company performance over the past year.

CEO

Brian Goff (54 yo)

1.8yrs

Tenure

US$3,416,453

Compensation

Mr. Brian M. Goff, M.B.A. is Chief Executive Officer and Director at Agios Pharmaceuticals, Inc. from August 08, 2022. He had been Executive Vice President at Alexion Pharmaceuticals, Inc. since June 01, 2...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Brian Goff	CEO & Director	1.8yrs	US$3.42m	0.095% $ 1.9m
Cecilia Jones	Chief Financial Officer	1.7yrs	US$1.21m	0.026% $ 512.6k
James Burns	Corporate Secretary & Chief Legal Officer	2.3yrs	US$1.93m	0.065% $ 1.3m
Sarah Gheuens	Chief Medical Officer and Head of Research & Development	2.7yrs	US$2.87m	0.069% $ 1.3m
Tsveta Milanova	Chief Commercial Officer	1.3yrs	US$3.73m	0.023% $ 457.1k
Lewis Cantley	Co-Founder & Member of Scientific Advisory Board	no data	US$333.51k	no data
Tak Mak	Co-Founder & Member of Scientific Advisory Board	no data	no data	no data
Craig Thompson	Co-Founder & Chairman of Scientific Advisory Board	no data	no data	no data
Shin-San Su	Co-Founder & Member of Scientific Advisory Board	no data	no data	no data
T. Washburn	Principal Accounting Officer	2.8yrs	no data	0.0051% $ 99.6k
Clive Patience	Chief Technical Operations Officer	6.9yrs	no data	no data
Christopher J. Taylor	Vice President of Investor Relations & Corporate Communications	no data	no data	no data

2.3yrs

Average Tenure

54yo

Average Age

Experienced Management: 0HB0's management team is considered experienced (2.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Brian Goff	CEO & Director	1.8yrs	US$3.42m	0.095% $ 1.9m
Lewis Cantley	Co-Founder & Member of Scientific Advisory Board	no data	US$333.51k	no data
Tak Mak	Co-Founder & Member of Scientific Advisory Board	no data	no data	no data
Craig Thompson	Co-Founder & Chairman of Scientific Advisory Board	no data	no data	no data
Shin-San Su	Co-Founder & Member of Scientific Advisory Board	no data	no data	no data
Jacqualyn Fouse	Chair of the Board of Directors	6.4yrs	US$447.25k	0.24% $ 4.7m
Jeffrey Capello	Independent Director	less than a year	US$663.68k	no data
Charles Sawyers	Member of Scientific Advisory Board	15.3yrs	no data	no data
Kaye Foster-Cheek	Lead Independent Director	9.4yrs	US$440.95k	0.014% $ 266.9k
David Schenkein	Independent Director	14.8yrs	US$417.25k	0.83% $ 16.3m
Matthew Vander Heiden	Member of Scientific Advisory Board	15.5yrs	no data	no data
Cynthia Smith	Independent Director	1.8yrs	US$419.91k	0.0040% $ 79.4k

7.9yrs

Average Tenure

64yo

Average Age

Experienced Board: 0HB0's board of directors are considered experienced (7.9 years average tenure).

Agios Pharmaceuticals Management

Management criteria checks 3/4

Key information

Recent management updates

Agios Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

Agios Pharmaceuticals, Inc. Announces Board Changes

Insufficient new directors

Agios Pharmaceuticals, Inc. Appoints Tsveta Milanova as Chief Commercial Officer, Effective Jan. 3, 2023

Agios Pharmaceuticals, Inc. Appoints Cecilia Jones as Chief Financial Officer, Effective September 26, 2022

Agios Pharmaceuticals, Inc. Announces Resignation of Jonathan Biller as Chief Financial Officer, Effective September 16, 2022

Recent updates

First quarter 2024 earnings released: US$1.45 loss per share (vs US$1.47 loss in 1Q 2023)

Agios Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

New minor risk - Shareholder dilution

Full year 2023 earnings released: US$6.33 loss per share (vs US$4.23 loss in FY 2022)

Agios Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Agios Pharmaceuticals, Inc. Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio

Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 2 Portion of the Rise Up Pivotal Study in Sickle Cell Disease at 65Th ASH Annual Meeting and Exposition

Agios Pharmaceuticals, Inc. Announces Clinical Proof-Of-Concept in Phase 2A Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes

Third quarter 2023 earnings released: US$1.64 loss per share (vs US$1.49 loss in 3Q 2022)

Agios Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Second quarter 2023 earnings released: US$1.51 loss per share (vs US$1.68 loss in 2Q 2022)

Agios Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Agios Pharmaceuticals, Inc. Announces Board Changes

Insufficient new directors

Agios Pharmaceuticals, Inc. Presents Updated PYRUKYND® (mitapivat) Long-term Extension Data Demonstrating Sustained Clinical Benefits in Adults with Pyruvate Kinase (PK) Deficiency at 64th ASH Annual Meeting and Exposition

Agios Pharmaceuticals, Inc. Appoints Tsveta Milanova as Chief Commercial Officer, Effective Jan. 3, 2023

Agios Pharmaceutical's PYRUKYND® Approves in the EU for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients

Agios Pharmaceuticals, Inc. Appoints Cecilia Jones as Chief Financial Officer, Effective September 26, 2022

Agios Pharmaceuticals, Inc. Receives Positive Chmp Opinion for Pyrukynd® (Mitapivat) for the Treatment of Pyruvate Kinase (Pk) Deficiency in Adult Patients

Agios Pharmaceuticals, Inc. Announces Resignation of Jonathan Biller as Chief Financial Officer, Effective September 16, 2022

Agios Pharmaceuticals, Inc. Appoints Rahul Ballal and Cynthia Smith to Board of Directors

Agios Pharmaceuticals, Inc. Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® (mitapivat) in Non-transfusion-dependent a- and ß-Thalassemia

Insufficient new directors

Agios Pharmaceuticals, Inc. Announces Management Changes, Effective August 8, 2022

Agios Presents New Clinical Data Supporting the Benefits of Pyrukynd® Treatment in Adults with PK Deficiency At European Hematology Association Annual Congress

Agios Pharmaceuticals, Inc. Announces Resignation of Bruce Car as Chief Scientific Officer, effective as of August 1, 2022

Agios Pharmaceuticals, Inc. Announces Management Changes

Agios Pharmaceuticals, Inc. Announces Executive Changes

Insufficient new directors

Agios Pharmaceuticals, Inc. Announces Resignation of Ian T. Clark from the Board

Agios Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 05, 2022

Insufficient new directors

Agios Pharmaceuticals, Inc. Announces FDA Approval of Pyrukynd (Mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency

Insufficient new directors

No longer forecast to breakeven

Insufficient new directors

No longer forecast to breakeven

Agios Pharmaceuticals, Inc. Presents Mitapivat Long-term Extension Data Demonstrating Durability of Hemoglobin Response and Transfusion Burden Reduction in Adults with Pyruvate Kinase (PK) Deficiency at 63rd ASH Annual Meeting and Exposition

Insufficient new directors

Forecast to breakeven in 2021

Forecast to breakeven in 2021

Agios Pharmaceuticals, Inc. Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

Principal Accounting Officer and VP of Accounting, Treasury & Tax Carman Alenson has left the company

Agios Pharmaceuticals, Inc.(NasdaqGS:AGIO) dropped from Russell Midcap Value Index

Agios Pharmaceuticals, Inc. Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 2 Study of Mitapivat in Non-Transfusion-Dependent a- and ß-Thalassemia at the European Hematology Association Virtual Congress

Forecast to breakeven in 2021

Insider recently sold US$192k worth of stock

Forecast to breakeven in 2021

Agios Reports Clinical Data Presentations

Agios Pharmaceuticals, Inc. Announces Closing of Oncology Business Sale to Servier

Agios Submits Supplemental New Drug Application to FDA for TIBSOVO® (ivosidenib tablets) for Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma

Revenue beats expectations

Full year 2020 earnings released: US$4.75 loss per share (vs US$6.86 loss in FY 2019)

Agios Pharmaceuticals, Inc. Announces the Appointment of Darrin Miles to Role of Chief Commercial Officer

Agios Announces Phase 3 ACTIVATE-T Trial of Mitapivat Achieved Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Regularly Transfused

Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma

Servier Pharmaceuticals, LLC entered into a definitive agreement to acquire oncology business from Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO) for $2 billion.

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age